United Therapeutics Adds Three New Members to Its Scientific Advisory Board

Apr 02, 2001, 01:00 ET from United Therapeutics Corporation

    SILVER SPRING, Md., April 2 /PRNewswire/ --
 United Therapeutics Corporation (Nasdaq:   UTHR) announced today that it is
 adding three members to its Scientific Advisory Board with the appointments of
 Victor J. Dzau, M.D., Louis Ignarro, Ph.D., and John Deanfield, MB, BChir,
 FRCP.
     Dr. Dzau is the Chairman of the Department of Medicine at Harvard
 University Medical School and is the physician in chief and director of
 research at Brigham and Women's Hospital in Boston.  Dr. Dzau is also a member
 of the Advisory Committee to the Director of the National Institutes of
 Health, Chairman of the Council of Arteriosclerosis, Thrombosis and Vascular
 Biology of the American Heart Association, and a member of the Institute of
 Medicine of the National Academy of Sciences.
     Prof. Ignarro won the Nobel Laureate in Medicine in 1998 for his work on
 Nitric Oxide's role in vascular health.  He is also a Professor in the
 Department of Pharmacology at UCLA School of Medicine.  Prof. Ignarro is a
 founder of the Nitric Oxide Society and editor-in-chief of the scientific
 journal Nitric Oxide, Biology and Chemistry.
     Prof. Deanfield is a Cardiologist at the Hospital for Children, a
 Professor at University College London and Chairman of The European Cardiology
 Society's Task Force on Congenital Heart Disease
     United Therapeutics Scientific Advisory Board provides the company with
 scientific vision, product guidance and industry contacts.  The Board is lead
 by Sir John Vane, D.Sc. F.R.S., founder of the William Harvey Research
 Institute.
     "We feel the addition of these three outstanding scientists will help
 expand out strategic drug development insight as well as open many new
 opportunities," commented Martine Rothblatt, Chairman and CEO of United
 Therapeutics Corporation.
 
     United Therapeutics is a biotechnology company focused on combating
 cardiovascular, inflammatory and infectious disease with unique therapeutic
 products.  United Therapeutics is a member of the Russell 3000 Index and is
 included in the iShares Nasdaq Biotechnology Index Fund (NBI).
 
 

SOURCE United Therapeutics Corporation
    SILVER SPRING, Md., April 2 /PRNewswire/ --
 United Therapeutics Corporation (Nasdaq:   UTHR) announced today that it is
 adding three members to its Scientific Advisory Board with the appointments of
 Victor J. Dzau, M.D., Louis Ignarro, Ph.D., and John Deanfield, MB, BChir,
 FRCP.
     Dr. Dzau is the Chairman of the Department of Medicine at Harvard
 University Medical School and is the physician in chief and director of
 research at Brigham and Women's Hospital in Boston.  Dr. Dzau is also a member
 of the Advisory Committee to the Director of the National Institutes of
 Health, Chairman of the Council of Arteriosclerosis, Thrombosis and Vascular
 Biology of the American Heart Association, and a member of the Institute of
 Medicine of the National Academy of Sciences.
     Prof. Ignarro won the Nobel Laureate in Medicine in 1998 for his work on
 Nitric Oxide's role in vascular health.  He is also a Professor in the
 Department of Pharmacology at UCLA School of Medicine.  Prof. Ignarro is a
 founder of the Nitric Oxide Society and editor-in-chief of the scientific
 journal Nitric Oxide, Biology and Chemistry.
     Prof. Deanfield is a Cardiologist at the Hospital for Children, a
 Professor at University College London and Chairman of The European Cardiology
 Society's Task Force on Congenital Heart Disease
     United Therapeutics Scientific Advisory Board provides the company with
 scientific vision, product guidance and industry contacts.  The Board is lead
 by Sir John Vane, D.Sc. F.R.S., founder of the William Harvey Research
 Institute.
     "We feel the addition of these three outstanding scientists will help
 expand out strategic drug development insight as well as open many new
 opportunities," commented Martine Rothblatt, Chairman and CEO of United
 Therapeutics Corporation.
 
     United Therapeutics is a biotechnology company focused on combating
 cardiovascular, inflammatory and infectious disease with unique therapeutic
 products.  United Therapeutics is a member of the Russell 3000 Index and is
 included in the iShares Nasdaq Biotechnology Index Fund (NBI).
 
 SOURCE  United Therapeutics Corporation